COMPANY
OmniaMed Co., Ltd. opens up a new paradigm for
the development of treatments using Nitric Oxide functionality.
OVERVIEW
Vision
Global company with competitive edge in developing Nitric Oxide drugs
-
Development Nitric Oxide-based BBB Transmittance
Augmentation Combination and global licensing out
-
→ Leading the development of original treatments in the
field of brain diseases that currently only relieve symptoms
-
Development of a first-in-class treatment based on a
clear identification of Nitric Oxide-immunity systems.
-
→ Development of Nitric Oxide as a treatment
for autoimmune diseases and cancer
What we do
OmniaMed Co., Ltd. opens up a new paradigm for the
development of treatments using Nitric Oxide functionality.
As a new key factor in the conquest of brain disease / autoimmune disease / cancer, Nitric Oxide is used to develop a first-in-class cure .
A New Paradigm in Treating
Diseases by Nitric Oxide Control
A number of original
technologies and excellent
research personnel
- Outstanding research personnel at POSTECH
- Source patents accumulated over many years.
- We make the most of POSTECH's optimized research infrastructure and start-up environment.
New drug
development company
specialized in NO
- Applicability of various diseases
- Global Blue Ocean
- World-class original NO-related research
First-in-class
New Drug Development
Related to NO
- New drug development through clinical trials
- Possible combination with various medications
- Transferring Big Pharma Target Technology
OmniaMed Co., Ltd. is
taking steps toward
developing new treatments.
OmniaMed : HISTORY
- 2021
-
- Mar.
- Completion of Drug Evaluation R&D Center
- Jan.
- Establishment of Seoul Branch Office
- 2020
-
- Oct.
- Venture company certification (Korea Venture Capital Association)
- Sep.
- Signing a research service with Pohang University Laboratory
- Aug.
- Attracting institutional investment
- Jul.
- Pohang innopolis R&D Special Zone Project Selection
- Apr.
- Technology transfer from IBS
- Apr.
- Attract angel investment
- Mar.
- Technology transfer from POSTECH
- 2019
-
- Dec.
-
Establishment of OmniaMed Co., Ltd. and inauguration of
CEO Won Jong Kim